Hakim Djaballah

Hakim Djaballah is a prominent figure in biochemistry and medical research, currently serving as a Founding Member at the laboratory of oxidative stress & associated complications of the kidney at Algiers University 1 since 2021. As the Founder, President, and CEO of Keren Therapeutics since 2016, Hakim leads the development of innovative technologies aimed at addressing the side effects of aging, particularly muscle fatigue and frailty in older adults. Additional roles include membership on the Scientific Advisory Board of the Ontario Institute for Cancer Research and SLAS, serving as a Managing Member at The Windeer Group, and participation on the External Advisory Board of UT Health Science Center’s Greehey Children's Cancer Research Institute. Hakim has also held significant advisory positions at Qurient, Inc., the Pasteur Institute of Iran, Institut Pasteur, and Institut Pasteur du Cambodge, emphasizing a strong commitment to advancing cancer research and addressing unmet medical needs. Educationally, Hakim holds a PhD in Biochemistry from the University of Leicester and a BSc (Hons) in Biochemistry with Biotechnology from the University of Birmingham.